AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PRESCIENT THERAPEUTICS LTD

0.047

0.000

Volume:3.64M

Turnover:171.32K

Market Cap:37.85M

PE:-5.36

High:0.049

Open:0.047

Low:0.044

Close:0.047

Loading ...

Overview Company News Filings

Prescient Therapeutics Completes Initiation Visit at US Site

MT Newswires Live

Prescient Therapeutics Ltd-Update - Proposed Issue of Securities - Ptx

THOMSON REUTERS

Notification of cessation of securities - PTX-PTX.AX

Notification of cessation of securities - PTX-PTX.AX

Prescient Share Purchase Plan Investor Presentation-PTX.AX

Prescient Therapeutics’ PTX-100 Progresses to Phase 2a Trials after Outstanding Phase 1b Results

ASX ALERT-Prescient Therapeutics Opens Share Purchase Plan-PTX.AX

BRIEF-Prescient Therapeutics To Raise A$7 Million

Prescient Therapeutics - to Raise a$7 Mln via a Share Purchase Plan at a$0.040 per Share

THOMSON REUTERS

Proposed issue of securities - PTX-PTX.AX

ASX ALERT-Prescient Therapeutics Launches Share Purchase Plan for $7m-PTX.AX

Prescient Doses First Patient in White Blood Cell Cancer Treatment Candidate Trial; Shares Rise 4%

MT Newswires Live

Prescient Therapeutics Receives Fast Track FDA Designation for Potential Lymphoma Treatment; Shares Up 5%

MT Newswires Live

BUZZ-Australia's Prescient Therapeutics gains on FDA fast-track status for cancer drug

BRIEF-Prescient Therapeutics' PTX-100 Receives U.S. FDA Fast Track Designation

Prescient Therapeutics Ltd - Ptx-100 Receives U.S. FDA Fast Track Designation

THOMSON REUTERS

Prescient Therapeutics Completes First Site Initiation Visit for Cancer Treatment Candidate Trial; Shares Up 7%

MT Newswires Live

Prescient Therapeutics Appoints Chief Medical Officer; Shares Down 4%

MT Newswires Live

Prescient Therapeutics Appoints Chair; Shares Fall 7%

MT Newswires Live

BRIEF-Prescient Therapeutics Says Steven Engle To Retire As Chair

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PTX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTX.AU\",,,,,undefined,":{"symbol":"PTX.AU","market":"AU","secType":"STK","nameCN":"PRESCIENT THERAPEUTICS LTD","latestPrice":0.047,"timestamp":1752819120000,"preClose":0.047,"halted":0,"volume":3640028,"delay":0,"nameEN":"PRESCIENT THERAPEUTICS LTD","floatShares":805319793,"shares":805319793,"eps":-0.008776,"marketStatus":"Market Closed","change":0,"latestTime":"07-18 16:12:00 AEST","open":0.047,"high":0.049,"low":0.044,"amount":171315,"amplitude":0.106383,"askPrice":0.049,"askSize":486590,"bidPrice":0.048,"bidSize":150000,"shortable":3,"etf":0,"ttmEps":-0.008776,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1753056000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.047,"openAndCloseTimeList":[[1752796800000,1752818400000]],"volumeRatio":1.9546792837145617,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTX.AU\",,,,,undefined,":{"symbol":"PTX.AU","floatShares":805319793,"roa":"-17.58%","roe":"-36.95%","lyrEps":-0.010229,"volumeRatio":1.9546792837145617,"shares":805319793,"dividePrice":0,"high":0.049,"amplitude":0.106383,"preClose":0.047,"low":0.044,"week52Low":0.037,"pbRate":"2.42","psRate":"12.53","week52High":0.063,"institutionHeld":0,"latestPrice":0.047,"committee":-0.528739,"eps":-0.008776,"divideRate":0,"volume":3640028,"delay":0,"ttmEps":-0.008776,"open":0.047,"prevYearClose":0.05,"prevWeekClose":0.042,"prevMonthClose":0.044,"prevQuarterClose":0.044,"fiveDayClose":0.042,"twentyDayClose":0.05,"sixtyDayClose":0.045},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551152621","title":"Prescient Therapeutics Completes Initiation Visit at US Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2551152621","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551152621?lang=en_us&edition=fundamental","pubTime":"2025-07-16 09:48","pubTimestamp":1752630522,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  has completed a site initiation visit at the VCU Massey Comprehensive Cancer Center in Virginia for its ongoing Phase 2a clinical trial of drug candidate PTX-100 in patients with relapsed or refractory cutaneous T-cell lymphoma, according to a Wednesday filing with the Australian bourse.Additional US sites are expected to be initiated in the coming weeks, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4539","BK7508","BK4139","LENZ","BK4007","PTX.AU"],"gpt_icon":0},{"id":"2551463130","title":"Prescient Therapeutics Ltd-Update - Proposed Issue of Securities - Ptx","url":"https://stock-news.laohu8.com/highlight/detail?id=2551463130","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551463130?lang=en_us&edition=fundamental","pubTime":"2025-07-15 11:01","pubTimestamp":1752548493,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nTUE8GK6VL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","PTX.AU"],"gpt_icon":0},{"id":"2551730719","title":"Notification of cessation of securities - PTX-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2551730719","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551730719?lang=en_us&edition=fundamental","pubTime":"2025-07-14 11:33","pubTimestamp":1752464008,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250714:nASXbq8yj3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nASX7PBwf6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","PTX.AU"],"gpt_icon":0},{"id":"2549598318","title":"Notification of cessation of securities - PTX-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2549598318","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549598318?lang=en_us&edition=fundamental","pubTime":"2025-07-08 10:00","pubTimestamp":1751940011,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250708:nASX9MkVPl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nASXy356Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2548333302","title":"Prescient Share Purchase Plan Investor Presentation-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548333302","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548333302?lang=en_us&edition=fundamental","pubTime":"2025-07-04 07:19","pubTimestamp":1751584763,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250703:nASX9JZ7D5","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nASX262Mb0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","PTX.AU"],"gpt_icon":0},{"id":"2548332903","title":"Prescient Therapeutics’ PTX-100 Progresses to Phase 2a Trials after Outstanding Phase 1b Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2548332903","media":"Small Caps","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548332903?lang=en_us&edition=fundamental","pubTime":"2025-07-04 07:19","pubTimestamp":1751584756,"startTime":"0","endTime":"0","summary":"Clinical-stage oncology company Prescient Therapeutics  is looking to disrupt a US$1.8 billion market on the back of outstanding Phase 1b clinical trial data for lead candidate PTX-100 to treat cutaneous T-cell lymphoma .Now in its Phase 2a trial, the advanced drug has delivered a 64% tumour halt or shrinkage in patients with the rare but relentless cancer, with only 4% reporting serious adverse effects.This compares to incumbent therapies which have demonstrated a 36% chance of any relief and adverse effects in 98% of patients.Chief executive officer James McDonnell said the trial results give Prescient a shot at becoming one of Australia’s biotech success stories.“PTX-100 has given us highly-encouraging clinical data and we are now looking to advance our clinical program toward registration,” he said.“It is an exciting development which could potentially be applied to 22% of all cancers, so there is a significant opportunity for us to touch millions of lives with this potentially lif","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/07/Prescient-Therapeutics-ASX-PTX-PTX-100-Phase-2a-Trials.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/07/Prescient-Therapeutics-ASX-PTX-PTX-100-Phase-2a-Trials.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/prescient-therapeutics-ptx-100-phase-2a-trials-outstanding-results/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["PTX.AU","BK7508","BK4539","BK7067","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2548354836","title":"ASX ALERT-Prescient Therapeutics Opens Share Purchase Plan-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548354836","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548354836?lang=en_us&edition=fundamental","pubTime":"2025-07-02 07:21","pubTimestamp":1751412096,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250701:nASX1jyFRD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nASX8bWFR4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","PTX.AU"],"gpt_icon":0},{"id":"2548046430","title":"BRIEF-Prescient Therapeutics To Raise A$7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2548046430","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548046430?lang=en_us&edition=fundamental","pubTime":"2025-07-01 07:26","pubTimestamp":1751325987,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics To Raise A$7 MillionJuly 1 (Reuters) - Prescient Therapeutics Ltd PTX.AX:TO RAISE A$7 MILLION VIA A SHARE PURCHASE PLAN AT A$0.040 PER SHAREFurther company coverage: PTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nFWN3SX14X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2548046558","title":"Prescient Therapeutics - to Raise a$7 Mln via a Share Purchase Plan at a$0.040 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2548046558","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548046558?lang=en_us&edition=fundamental","pubTime":"2025-07-01 07:10","pubTimestamp":1751325044,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nFWN3SX14X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","PTX.AU"],"gpt_icon":0},{"id":"2548462260","title":"Proposed issue of securities - PTX-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548462260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548462260?lang=en_us&edition=fundamental","pubTime":"2025-07-01 07:10","pubTimestamp":1751325044,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASX287WSg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASX708S3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTX.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2548046240","title":"ASX ALERT-Prescient Therapeutics Launches Share Purchase Plan for $7m-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548046240","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548046240?lang=en_us&edition=fundamental","pubTime":"2025-07-01 07:10","pubTimestamp":1751325026,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASX8yFZV9","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASX8p6bzP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTX.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2538487409","title":"Prescient Doses First Patient in White Blood Cell Cancer Treatment Candidate Trial; Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2538487409","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538487409?lang=en_us&edition=fundamental","pubTime":"2025-05-27 10:20","pubTimestamp":1748312448,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics (ASX:PTX) has dosed the first patient in its phase 2a clinical study of cancer treatment candidate PTX-100, a compound with the ability to block an important cancer growth enzym","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTX.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2528329537","title":"Prescient Therapeutics Receives Fast Track FDA Designation for Potential Lymphoma Treatment; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528329537","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528329537?lang=en_us&edition=fundamental","pubTime":"2025-04-17 12:18","pubTimestamp":1744863516,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  received a fast-track designation from the US Food and Drug Administration for its PTX-100 compound for the potential treatment of adults with relapsed or refractory mycosis fungoides, according to a Wednesday filing with the Australian bourse.The designation will expedite the review of therapies for serious conditions with high unmet need, enabling earlier delivery to patients, the filing said.Mycosis fungoides is a subtype of cutaneous T-cell lymphoma, a group of rare blood cancers affecting the skin.Shares rose nearly 5% in afternoon trade Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK4139","BK4104","LENZ","IE00BYQQ9H92.USD","IE00B5TLWC47.USD","FAST","BK4007","PTX.AU","BK7067","IE00BFXG0V08.USD","BK4585","BK4567","BK4588"],"gpt_icon":0},{"id":"2527401260","title":"BUZZ-Australia's Prescient Therapeutics gains on FDA fast-track status for cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2527401260","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527401260?lang=en_us&edition=fundamental","pubTime":"2025-04-16 09:35","pubTimestamp":1744767341,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Prescient Therapeutics gains on FDA fast-track status for cancer drug** Shares of Prescient Therapeutics PTX.AX rise as much as 28.6% to A$0.054, hit their highest levels since February 11** The clinical-stage oncology co says it received the US FDA Fast-Track designation for PTX-100, a treatment for adults with relapsed or refractory mycosis fungoides** PTX-100 is a compound with the ability to block an important cancer growth enzyme, says co** The fast-track status is an important step towards commercialisation of the drug, says co** About 2.7 million shares change hands, 4.3 times the 30-day average volume of shares** Stock down 16% this year, as of last close  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nL4N3QU034:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2527547722","title":"BRIEF-Prescient Therapeutics' PTX-100 Receives U.S. FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527547722","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527547722?lang=en_us&edition=fundamental","pubTime":"2025-04-16 08:00","pubTimestamp":1744761636,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics' PTX-100 Receives U.S. FDA Fast Track DesignationApril 16 (Reuters) - Prescient Therapeutics Ltd PTX.AX:PTX-100 RECEIVES U.S. FDA FAST TRACK DESIGNATIONFurther company coverage: PTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QT2HJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2527547420","title":"Prescient Therapeutics Ltd - Ptx-100 Receives U.S. FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527547420","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527547420?lang=en_us&edition=fundamental","pubTime":"2025-04-16 07:20","pubTimestamp":1744759230,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT2HJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2522866954","title":"Prescient Therapeutics Completes First Site Initiation Visit for Cancer Treatment Candidate Trial; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522866954","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522866954?lang=en_us&edition=fundamental","pubTime":"2025-03-26 10:52","pubTimestamp":1742957523,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics (ASX:PTX) completed the first site initiation visit of its phase 2a clinical study of cancer treatment candidate PTX-100, according to a Wednesday filing with the Australian bou","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTX.AU","BK7067","BK4139","LENZ","BK7508"],"gpt_icon":0},{"id":"2521731388","title":"Prescient Therapeutics Appoints Chief Medical Officer; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2521731388","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521731388?lang=en_us&edition=fundamental","pubTime":"2025-03-24 09:56","pubTimestamp":1742781393,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  appointed Marissa Lim as Chief Medical Officer, effective Monday, according to a same-day filing with the Australian bourse.Lim succeeds CMO Terrence Chew, who will continue with the company in an advisory capacity, per the filing.The clinical-stage oncology company's shares were down 4% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","BK7508","BK4139","LENZ","PTX.AU","BK7067","XAO.AU","XKO.AU"],"gpt_icon":0},{"id":"2518736088","title":"Prescient Therapeutics Appoints Chair; Shares Fall 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518736088","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518736088?lang=en_us&edition=fundamental","pubTime":"2025-03-11 09:22","pubTimestamp":1741656156,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics (ASX:PTX) appointed Non-Executive Director James Campbel as Chair, effective March 30, according to a Tuesday filing with the Australian bourse.Campbel will succeed former Chair Steven Engle, the filing said.Shares of the company fell past 7% in recent Tuesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","XJO.AU","XAO.AU","BK7067","LENZ","BK7508","PTX.AU","XKO.AU"],"gpt_icon":0},{"id":"2518705736","title":"BRIEF-Prescient Therapeutics Says Steven Engle To Retire As Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2518705736","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518705736?lang=en_us&edition=fundamental","pubTime":"2025-03-11 09:21","pubTimestamp":1741656090,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics Says Steven Engle To Retire As ChairMarch 11 (Reuters) - Prescient Therapeutics Ltd PTX.AX:STEVEN ENGLE TO RETIRE AS CHAIR OF PRESCIENT THERAPEUTICS ON 30 MARCH 2025DR JAM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PT12F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PTX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTX.AU\",market:\"AU\",,,undefined,":[]}}